Asymchem Laboratories (Tianjin) Co., Ltd.

Asymchem Laboratories (Tianjin) Co., Ltd. is a prominent contract development and manufacturing organization (CDMO) based in China, specializing in comprehensive solutions for drug development and manufacturing. Established in 2016 and listed on the Shenzhen Stock Exchange, the company has over two decades of experience in small molecule drug development and has positioned itself as a key player in the global pharmaceutical value chain. Asymchem is committed to leveraging advanced technologies and extensive industry knowledge to support pharmaceutical companies throughout the entire lifecycle of drug development. The company's main business lines include small molecule drug development, as well as emerging services such as peptides, oligonucleotides, monoclonal antibodies, and messenger RNA. Asymchem has built strong relationships with leading global biopharmaceutical companies, enhancing its service capabilities and expanding into new modalities. With a focus on technological leadership and a rigorous quality management system, Asymchem aims to address complex process challenges in drug production, thereby accelerating clinical development and ensuring high-quality outcomes for its clients.

Leveraging Asymchem’s management team’s global vision, intensive strategy, and local expertise, Asymchem is well positioned to capture the growing trend of global CDMO outsourcing to China, with its technological leadership and extensive know-how, established long-term relationships with global leading biopharma/biotechnology companies, as well as service capability expansion into new modalities and service types. We have continued to develop as a technology driven CDMO providing comprehensive solutions with strong revenue growth performance of the flagship services through small molecule and emerging business services. Asymchem has amassed over decades of experience and solidified its position in the small molecule business. Our collaborations with international multinational pharmaceutical companies have grown stronger. We strive to further advance our market leadership in the small molecule CDMO market through the established reputation, advanced R&D platforms, robust manufacturing capabilities and high-quality customer services to diversified multinational pharmaceutical companies and leading biotechnology companies across different jurisdictions. Derived from six business lines of the emerging services segment, we spotted on peptide and oligonucleotide in chemical macromolecules, captured the blooming of biological macromolecules through integration service of ADC, various conjugated drugs, and payload linkers, and promoted export continuous flow technology and synthetic biology Technology. The two flagship technologies have evolved from individual components into full-fledged technological platforms. We can now offer external technology output, enabling partners from diverse fields to leverage our cutting-edge technological achievements to address their own pain points, leading to notable enhancements in efficiency and safety while significantly reducing costs. By leveraging the deep industry insights, we will continue to push forward emerging business, which we believe will drive the diauxic growth curve of the Company through the number of blockbuster drugs and several drug candidates of our other innovative projects which hold great promise to become blockbuster drugs in the future. We have enriched the first-class operational and quality management capabilities meeting the stringent requirements from clients and global industry standards and have built a decent industry reputation. Our extensive technical know-how in process development makes us a preferred choice for large customers. We can expediently solve a variety of complex process challenges in the scale-up production of innovative drugs, accelerating clinical development process and providing high-quality enhancement of yield and stable production during the commercial stage. Based on years of largescale manufacturing experience, we have established a comprehensive, rigorous Current Good Manufacture Practices (“cGMP”) quality system and a first-class environmental, health, and safety (“EHS”) and quality assurance (“QA”) system. In the past, we have an outstanding track record of ESH and EA system compliance and further extensive improvement and development on the rapid upgrading of supplier requirements from several clients i.e. multiple pharmaceutical companies through their individual ESG standards. We have maintained a stable, visionary, experienced senior executive management team who have long-term industry and operation experience with a sophisticated corporate governance sense, supported by talented and dedicated employees. Our Company is led by the founder, Chairperson, and CEO Dr. Hao Hong and a group of senior executives with an average of more than 20 years of profound experience in their respective fields. The management team is also very stable with multiple members joining during the early days of the Company and several others who have been at the Company for over 10 years. Combined with the diversified talent pool and employees with a global vision, advanced technical knowledge, sturdy execution capabilities, and a strong sense of ownership, it is likely to continue driving the Company’s growth.